New chemoselective peptide heterodimerization and cyclization reactions for the development of novel PET radiopharmaceuticals

用于开发新型 PET 放射性药物的新型化学选择性肽异二聚化和环化反应

• 批准号: 341572-2008
• 负责人: Guérin, Brigitte
• 金额: $ 2.04万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=458456
• 关键词: New; chemoselective; peptide; heterodimerization; cyclization

Positron emission tomography (PET) is a powerful diagnostic tool for the detection and follow-up of many medical conditions including cancer, heart problems and neurological disorders. The procedure requires the administration of a radiopharmaceutical prior to the PET scan and novel radiopharmaceuticals for the detection of specific medical problems are required to fully exploit this novel diagnostic tool. Peptide hormone receptors expressed in different medical conditions are of particular interest for the development of new, more specific radiopharmaceuticals. The object of this research program is to develop alternative synthetic approaches for the synthesis of a variety of novel peptide derivatives that can subsequently serve as tracers for improved,

正电子发射断层扫描（PET）是一种有力的诊断工具，可检测和随访许多医疗状况，包括癌症，心脏问题和神经系统疾病。该程序需要在PET扫描之前对放射性药物进行施用，并需要进行新的放射性药物来检测特定的医学问题，以充分利用这种新型的诊断工具。在不同的医疗状况中表达的肽激素受体对于开发新的，更具体的放射性药物特别感兴趣。该研究计划的目的是开发替代合成方法来合成各种新型肽衍生物，这些方法随后可以作为改进的示踪剂，以改善，